All In Biotech

Drug Trial Radar · NCT06395519

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

May 13, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
858 Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

Conditions

  • Advanced or Metastatic Solid Tumors
  • Breast Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Epithelial Ovarian Cancer
  • BRCA2 Mutation
  • ER+ Breast Cancer
  • Castrate Resistant Prostate Cancer
  • BRCA1 Mutation
  • BRCA Mutation
  • Endometrial Cancer
  • Colorectal Cancer
  • Gastric Cancer

Interventions

  • ETX-19477Drug

    Oral medication taken daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To characterize the safety and tolerability of ETX-19477, the maximum tolerated dose (MTD) and/or RP2D of ETX-19477Time frame: 6 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona · Recruiting

  • Yale University, Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Stefanie Spielman Comprehensive Breast Center

    Columbus, Ohio · Recruiting

  • Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • START Center for Cancer Care - Mountain Region

    Salt Lake City, Utah · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.